The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a recall for Dove Beauty Cream Bar Soap following the discovery of a chemical impurity.
The specific product in question is the Dove Beauty Cream Bar Soap (100g), batch number 81832M 08, produced in Germany. NAFDAC has placed this product under stringent supervision due to non-compliance with Cosmetic Products Regulation.
The agency identified that the soap contains Butylphenyl Methylpropional (BMHCA), commonly known as Lilial. This chemical has been prohibited in cosmetics due to its association with significant health risks, including reproductive harm and potential effects on unborn children. It is also known to cause skin sensitization, leading to allergic reactions in some users.
Read Also: EFCC to take action against senior bankers for financial crimes
NAFDAC’s statement noted, “The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting the public about the recall of Dove Beauty Cream Bar Soap (100g), batch number 81832M 08, produced in Germany, due to the presence of a chemical impurity.”
The agency further explained that BMHCA has been banned by several regulatory authorities in the EU because of its potential dangers. The recall also affects other Dove cosmetic products internationally, including Derma Spa Goodness, Men Care, Men Care+ Sensitive Shield, Natural Touch, Nourishing Body Care Light Hydro, Pampering Body Lotion, Go Fresh variants, and others.
NAFDAC has urged the public to be cautious and vigilant in the supply chain to prevent the importation, distribution, sale, and use of these affected products. The agency emphasized that the importation of soaps is restricted in Nigeria and that soaps and cosmetics are not eligible for foreign exchange for importation.
The statement added, “These products are not listed in the NAFDAC database. Importers, distributors, retailers, and consumers are advised to exercise extreme caution. Those in possession of the product should cease sale or use and return any stock to the nearest NAFDAC office.”
NAFDAC also called on health professionals to report any adverse reactions from using regulated products to their nearest office.
